tirzepatide and thyroid medication Nodules: Safety Evidence and Guidelines Compounded Tirzepatide Weight Loss Program

A.YoungA.GillR.AburasaynH.et al (2021)

We primarily examined if GLP-1RAs can achieve corticosteroid-free clinical remission without altering the underlying immunosuppressive therapy in IBD, and secondarily if GLP-1RA therapy can improve IBD outcomes such as reducing corticosteroid use, hospitalizations, surgeries, and advanced therapies

A medication that is safe for one person might be inappropriate for another based on their unique biology

While joint pain relief is not an FDA-approved indication for GLP-1 medications, emerging clinical observations and patient reports have prompted investigation into potential musculoskeletal benefits

GI adverse events that occurred in postmenopausal women with operable breast cancer who received adjuvant tamoxifen therapy (n = 3094) in the ATAC trial include nausea and vomiting (12%), nausea (11%), abdominal pain (9%), constipation (8%), diarrhea (7%), dyspepsia (6%), and GI disorder (5%)